{"nctId":"NCT03329508","briefTitle":"A Phase 3 Study With P2B001 in Subjects With Early Parkinson's","startDateStruct":{"date":"2018-01-19","type":"ACTUAL"},"conditions":["Parkinson Disease","Early Parkinson's Disease"],"count":544,"armGroups":[{"label":"P2B001 0.6/0.75 mg","type":"EXPERIMENTAL","interventionNames":["Drug: P2B001 0.6/0.75 mg"]},{"label":"rasagiline 0.75mg","type":"EXPERIMENTAL","interventionNames":["Drug: Rasagiline 0.75 mg"]},{"label":"Pramipexole 0.6mg","type":"EXPERIMENTAL","interventionNames":["Drug: Pramipexole 0.6 mg"]},{"label":"Pramipexole Extended Release","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Marketed Pramipexole ER"]}],"interventions":[{"name":"P2B001 0.6/0.75 mg","otherNames":["P2B001 capsule"]},{"name":"Rasagiline 0.75 mg","otherNames":["RAS 0.75"]},{"name":"Pramipexole 0.6 mg","otherNames":["PPX 0.6"]},{"name":"Marketed Pramipexole ER","otherNames":["PramiER"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject has Parkinson's disease consistent with the UK Brain Bank Criteria and must have bradykinesia with sequence effect. If rest tremor does not exist must have prominent asymmetry of motor function.\n2. Subject with disease duration less than 3 years since diagnosis.\n3. Subject has a H\\&Y stage score of \\< 3.\n4. Subject has a MMSE score â‰¥ 26.\n\nExclusion Criteria:\n\n1. Subject has an atypical parkinsonian syndrome or secondary parkinsonism\n2. Subject has previous exposure to levodopa or a dopamine agonist for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 2 months prior to the baseline visit.\n3. Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 3 months prior to the baseline visit.\n4. Subject who has taken anticholinergic drugs for PD or amantadine for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 1 month prior to the baseline visit.\n5. Subject has moderate (Child-Pugh categorization B, score 7-9) or severe (Child-Pugh categorization C, score 10-15) hepatic impairment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160).","description":"Differences between P2B 0.6/0.75 mg as compared to its individual components in the change of total UPDRS score (defined as sum of parts II and III, scores (0-160).\n\nUPDRS- Unified Parkinson's Disease Rating Scale, minimum value is 0 points and maximum value is 160.\n\nHigh score mean worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.98","spread":"0.60"},{"groupId":"OG001","value":"-4.69","spread":"0.61"},{"groupId":"OG002","value":"-5.32","spread":"0.61"},{"groupId":"OG003","value":"-8.35","spread":"0.86"}]}]}]},{"type":"SECONDARY","title":"Change in Epworth Sleepiness Scale (ESS) Score.","description":"Differences between P2B 0.6/0.75 mg as compared to pramipexole ER tablets in the change of Epworth Sleepiness Scale (ESS) score.\n\nScale is 0-24 , when 24 is worse outcome","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.25"},{"groupId":"OG001","value":"-0.81","spread":"0.26"},{"groupId":"OG002","value":"0.39","spread":"0.25"},{"groupId":"OG003","value":"2.33","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 in Total UPDRS III Motor","description":"Differences between P2B 0.6/0.75 mg as compared to its individual components in the change of Motor UPDRS score (UPDRS Part III ).\n\nUPDRS- Unified Parkinson's Disease Rating Scale, part III motor . min is 0 and Max is 108 (Worse outcome)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.82","spread":"0.47"},{"groupId":"OG001","value":"-4.07","spread":"0.48"},{"groupId":"OG002","value":"-4.30","spread":"0.48"},{"groupId":"OG003","value":"-6.36","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 in Total UPDRS II ADL","description":"Differences between of P2B 0.6/0.75 mg as compared to its individual components in the change of ADL UPDRS score (UPDRS part II) Activity of daily Life UPDRS part II minimum is 0 point and max is 52 point (worse outcome)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.14","spread":"0.22"},{"groupId":"OG001","value":"-0.62","spread":"0.22"},{"groupId":"OG002","value":"-0.97","spread":"0.22"},{"groupId":"OG003","value":"-2.02","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End of Week 12 Visit in ADL Subscale of PDQ39","description":"The efficacy of P2B 0.6/0.75 mg as compared to Pramipexole ER tablet titrated to optimal dose.\n\nADL PDQ39- Activity of daily life part in Parkinson's Disease Questionaries' 39 Score 0-100 when 100 is the worse outcome","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.30","spread":"0.89"},{"groupId":"OG001","value":"-2.04","spread":"0.92"},{"groupId":"OG002","value":"-3.40","spread":"0.90"},{"groupId":"OG003","value":"-3.12","spread":"1.27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":150},"commonTop":["nausea","somnolence","fatigue","dizziness","headache"]}}}